Generic Name and Formulations:
Lipid content 0.2g/mL (mixture of refined olive oil and soybean oil [4:1]); emulsion for IV infusion; contains aluminum.
Indications for CLINOLIPID:
To provide a source of calories and essential fatty acids in adults requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Individualize. Dose based on patient’s energy expenditure, clinical status, body wt, tolerance, ability to metabolize Clinolipid, and additional energy given orally/enterally. Administer by IV infusion via central or peripheral vein. Usual dose: 1–1.5g/kg/day (5–7.5mL/kg/day); max: 2.5g/kg/day. Initiate rate at max 0.5mL/min for the first 15–30mins; increase gradually to required rate after 30mins. Usual infusion duration: 12–24 hours based on patient’s clinical status. If serum triglycerides (>400mg/dL): initiate at a lower dose and increase in smaller increments; check levels before each adjustment. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, vitamins and trace elements.
Egg or soybean allergy. Severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1000mg/dL).
Risk of deaths in preterm and low birth weight infants: see full labeling. Correct severe fluid and electrolyte disorders, fluid overload states, and metabolic disorders prior to initiating. Measure serum triglycerides at baseline, with each dose increase, and regularly during therapy. Discontinue and treat if hypersensitivity reactions occur. Monitor for signs/symptoms of infection and essential fatty acid deficiency (EFAD). Severely undernourished: avoid overfeeding. Patients with pulmonary edema, heart failure: monitor fluid status closely. Risk of Parenteral Nutrition Associated Liver Disease (PNALD); consider discontinuation or dose reduction if abnormal LFTs occur. Monitor fluids, electrolytes, serum osmolarity, blood glucose, liver and kidney function, CBCs, platelets, coagulation parameters throughout treatment. Hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Vitamin K content may antagonize anticoagulants (eg, coumarin, warfarin); monitor. High lipid levels in plasma may interfere with the results of certain blood tests. May precipitate if mixed with dextrose and/or amino acid solutions; check compatibility.
Nausea, vomiting, hyperlipidemia, hyperglycemia, hypoproteinemia, abnormal LFTs; hypersensitivity reactions, infections, refeeding syndrome, PNALD, hypertriglyceridemia, aluminum toxicity (esp. preterm infants, renal impairment); rare: fat overload syndrome.
Emulsion (1000mL)—1, 6
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|